PubMed 19. Udatsu Y, et al.: High frequency of beta-catenin mutations in hepatoblastoma. Pediatr Surg Int 2001,17(7):508–12.PubMedCrossRef 20. Kimelman D, Xu W: beta-catenin destruction https://www.selleckchem.com/products/Belinostat.html complex: insights and questions from a structural perspective. Oncogene 2006,25(57):7482–91.PubMedCrossRef Hydroxylase inhibitor 21. Nelson WJ, Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004,303(5663):1483–7.PubMedCrossRef 22. Apte U, et al.: beta-Catenin is critical for early postnatal liver growth. Am J Physiol Gastrointest Liver Physiol 2007,292(6):G1578–85.PubMedCrossRef 23. Nejak-Bowen

K, Monga SP: Wnt/beta-catenin signaling in hepatic organogenesis. Organogenesis 2008,4(2):92–9.PubMedCrossRef 24. Shang XZ, et al.: Stabilized beta-catenin Acalabrutinib cell line promotes hepatocyte proliferation and inhibits TNFalpha-induced apoptosis. Lab Invest 2004. 25. Inukai T, et al.: Nuclear accumulation of beta-catenin without an additional somatic mutation in coding region of the APC gene in hepatoblastoma from a familial adenomatous polyposis patient. [Review] [40 refs]. Oncology Reports 2004,11(1):121–6.PubMed 26. Ranganathan S, Tan X, Monga SP: beta-Catenin and met deregulation in childhood Hepatoblastomas. Pediatric & Developmental Pathology 2005,8(4):435–47.CrossRef 27. Monga SP, et al.: Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002,62(7):2064–71.PubMed

28. Zeng G, et al.: Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions. Exp Cell Res 2006,312(18):3620–30.PubMedCrossRef

Histone demethylase 29. Peruzzi B, Bottaro DP: Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006,12(12):3657–60.PubMedCrossRef 30. von Schweinitz D, et al.: The occurrence of liver growth factor in hepatoblastoma. Eur J Pediatr Surg 1998,8(3):133–6.PubMedCrossRef 31. von Schweinitz D, et al.: Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepatoblastoma. Int J Cancer 2000,85(2):151–9.PubMed 32. Danilkovitch-Miagkova A, et al.: Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell Biol 2001,21(17):5857–68.PubMedCrossRef 33. Perilongo G, et al.: Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009,361(17):1662–70.PubMedCrossRef 34. Zsiros J, et al.: Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 2010,17(1B):561–7. 35. Buendia MA: Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. [Review] [69 refs]. Medical & Pediatric Oncology 2002,39(5):530–5.CrossRef 36. Curia MC, et al.: Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations.